Xcell Therapeutics
Financials
Valuation Metrics
Xcell Therapeutics's Market Cap is ₩172B. At end of 2025 it was ₩287B. Ranked #2336 of 2,405 in KR market (top 97%), #1571 of 1,627 on KOSDAQ (top 97%), #227 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 98%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 17.24B KRW | KR#2,336/2,405 Sec#227/231 |
| Revenue | 4.36B KRW | KR#2,334/2,405 Sec#200/231 |
| Net Income | -11.37B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 12.63B KRW | KR#2,381/2,405 Sec#228/231 |
| Net Assets | 4.33B KRW | KR#2,379/2,405 Sec#228/231 |
| Employees | 68 | KR#1,899/2,405 Sec#166/231 |
| Value | ||
| P/B | 3.99x | KR#2,207/2,405 Sec#188/231 |
| P/S | 3.96x | KR#2,098/2,405 Sec#137/231 |
| FCF Yield | -60.13% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROA | -90.00% | KR#2,379/2,405 Sec#226/231 |
| Op. Margin | -259.36% | KR#2,327/2,405 Sec#191/231 |
| Revenue Growth | 193.30% | KR#42/2,405 Sec#10/231 |
| Financial Health | ||
| Debt Ratio | 191.88% | KR#2,066/2,405 Sec#215/231 |
| Total Debt | 4.57B KRW | KR#1,796/2,405 Sec#174/231 |
| FCF | -10.37B KRW | KR#1,711/2,405 Sec#151/231 |
| Cash | 3.93B KRW | KR#2,087/2,405 Sec#196/231 |
| Current Ratio | 1.28x | KR#1,411/2,405 Sec#149/231 |
| Performance | ||
| 1Y Return | -54.99% | KR#2,040/2,405 Sec#179/231 |
| 1M Return | 0.40% | KR#307/2,405 Sec#33/231 |
| From 52W High | -58.37% | KR#1,580/2,405 Sec#129/231 |
| 1Y MDD | -56.95% | KR#1,266/2,405 Sec#105/231 |
| Trading | ||
| Volume | 12,857 shares | KR#1,732/2,405 Sec#169/231 |
| Trading Value | 12.7M KRW | KR#2,199/2,405 Sec#224/231 |
| Foreign Own. | 1.58% | KR#1,792/2,405 Sec#176/231 |
| Per Share | ||
| EPS | -657 KRW | KR—/2,405 Sec—/231 |
| BPS | 250 KRW | KR#2,396/2,405 Sec#231/231 |
Company Info
Excell Therapeutics, established in 2015 and listed on KOSDAQ in 2024 as a technology growth company, specializes in cell culture media. The company primarily manufactures and supplies chemically defined media, 'CellCor', which excludes animal and human-derived substances crucial for the cell and gene therapy industry, from its GMP production facilities. It has developed the cell-customized medium development platform technology XPorT and is expanding its business into advanced biopharmaceuticals. Excell Therapeutics is headquartered in Gangnam-gu, Seoul.